---
title: Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors
date: '2023-07-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37490213/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230725180838&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Janus kinase inhibitors (JAKi) have enormous appeal as immune-modulating
  therapies across many chronic inflammatory diseases, but recently this promise has
  been overshadowed by questions regarding associated cardiovascular and cancer risk
  emerging from the ORAL Surveillance phase 3b/4 post-marketing requirement randomized
  controlled trial. In that study of patients with rheumatoid arthritis with existing
  cardiovascular risk, tofacitinib, the first JAKi registered for chronic ...
disable_comments: true
---
Janus kinase inhibitors (JAKi) have enormous appeal as immune-modulating therapies across many chronic inflammatory diseases, but recently this promise has been overshadowed by questions regarding associated cardiovascular and cancer risk emerging from the ORAL Surveillance phase 3b/4 post-marketing requirement randomized controlled trial. In that study of patients with rheumatoid arthritis with existing cardiovascular risk, tofacitinib, the first JAKi registered for chronic ...